RiverVest is the famous VC, which was founded in 2000. The venture was found in North America in United States. The main department of described VC is located in the St Louis.
The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 3 or 4 of the founder, the chance for it to get the investment is meager. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. We can highlight the next thriving fund investment areas, such as Health Diagnostics, Manufacturing. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight ZS Pharma, Arch Oncology, OncoResponse.
The fund was created by Jay W. Schmelter. The overall number of key employees were 6.
Opposing the other organizations, this RiverVest works on 3 percentage points less the average amount of lead investments. The top activity for fund was in 2014. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2011. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the RiverVest, startups are often financed by Cultivation Capital, Alta Partners, PTV Healthcare Capital. The meaningful sponsors for the fund in investment in the same round are Alta Partners, Arnerich Massena & Associates, 3x5 Special Opportunity Fund. In the next rounds fund is usually obtained by 3x5 Special Opportunity Fund, Alta Partners, Arnerich Massena & Associates.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Advisors.fund | California, San Francisco, United States |
| Alphabit Fund | California, San Francisco, United States |
| Beijing Liyue Jinshi Investment Center (LP) | Beijing, Beijing, China |
| FMC.COM Investment Holdings | China, Hong Kong, Hong Kong Island |
| Globalive Technology | - |
| HKMN LLC | - |
| Hudson Structured Capital Management | Connecticut, Stamford, United States |
| HyogoBenderEngineering | Himeji, Hyogo Prefecture, Japan |
| Infinite Capital LLC | Ohio, Rocky River, United States |
| INV Fintech | New York, New York, United States |
| Invaluable | Allston, Massachusetts, United States |
| Knightsgate Ventures | - |
| Leoch Battery | China, Guangdong, Shenzhen |
| Link Hui Capital | - |
| ORBITAL Space Investment Vehicle | - |
| Pechel Industries Partenaires | France, Ile-de-France, Paris |
| PIMCO | California, Newport Beach, United States |
| Shanghai Qianyi Investment Management | China, Shanghai |
| Southern Ontario Fund for Investment in Innovation (SOFII) | - |
| Winterpoint | Alabama, Birmingham, United States |
Discover 4 more decision makers Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
InterVene | 07 Oct 2024 | South San Francisco, California, United States | |||
Bluejay Therapeutics | $182M | 09 May 2024 | - | ||
OWL | $157M | 19 Mar 2024 | Bielefeld, Nordrhein-Westfalen, Germany | ||
Avalyn Pharma | $175M | 27 Sep 2023 | Seattle, Washington, United States | ||
Bonum Therapeutics | $93M | 15 Nov 2022 | Seattle, Washington, United States | ||
Bluejay Therapeutics | $41M | 16 Aug 2022 | - | ||
Good Therapeutics | $8M | 30 Dec 2021 | Seattle, Washington, United States | ||
Biolinq | $100M | 02 Nov 2021 | San Diego, California, United States | ||
Scout Bio | $33M | 19 Oct 2021 | Philadelphia, Pennsylvania, United States |
– SeQure Dx is a gene-editing diagnostics company.
– It announced a $17.5m Series A funding.
– The funding was led by RiverVest Venture Partners and Mass General Brigham Ventures along with Digitalis Ventures, Casdin Capital, KdT Ventures, Bold Capital Partners and Alexandria Venture Investments.
– Funds will be used for initial company development leading to establishment of a full-service laboratory providing off-target gene-editing analysis for use in drug development, clinical trials and ultimately patient evaluation prior to therapy.
– SeQure Dx was founded on exclusive licensure of GUIDE-seq, ONE-seq and related assay technologies for detection of off-target gene-editing events.
– Wugen, Inc. completed an oversubscribed $172m Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management and Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.
– Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated.
– In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
InterVene | 07 Oct 2024 | South San Francisco, California, United States | |||
Bluejay Therapeutics | $182M | 09 May 2024 | - | ||
OWL | $157M | 19 Mar 2024 | Bielefeld, Nordrhein-Westfalen, Germany | ||
Avalyn Pharma | $175M | 27 Sep 2023 | Seattle, Washington, United States | ||
Bonum Therapeutics | $93M | 15 Nov 2022 | Seattle, Washington, United States | ||
Bluejay Therapeutics | $41M | 16 Aug 2022 | - | ||
Good Therapeutics | $8M | 30 Dec 2021 | Seattle, Washington, United States | ||
Biolinq | $100M | 02 Nov 2021 | San Diego, California, United States | ||
Scout Bio | $33M | 19 Oct 2021 | Philadelphia, Pennsylvania, United States |
